302 Results

People

  1. Motzer
    Motzer
  2. Kris
    Kris
  3. Drilon
    Drilon
  4. Zelenetz
    Zelenetz
  5. Gerecitano
    Gerecitano
  6. Horwitz
    Horwitz
  7. Hudis
    Hudis
  8. Miller
    Miller
  9. Moskowitz
    Moskowitz
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)
  7. GSK Faculty (35)
  8. Survivorship Research (34)
  9. Biostatistics Service (32)
  10. Radiology, Department of (31)
  1. "coughing"
Formats
  1. Journal Article (285)
  2. Review (7)
  3. Research Letter (5)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)

More Groups

People
  1. Robert Motzer (22)
  2. Mark Kris (12)
  3. Alexander Drilon (9)
  4. Andrew Zelenetz (9)
  5. Clifford Hudis (8)
  6. John Gerecitano (8)

More People

Years
  1. 2025 (9)
  2. 2024 (24)
  3. 2023 (25)
  4. 2022 (18)
  5. 2021 (14)
  6. 2020 (30)

More Years

Publications
  1. Lancet Oncology (23)
  2. Clinical Cancer Research (22)
  3. Journal of Clinical Oncology (16)
  4. New England Journal of Medicine (15)
  5. Blood (13)
  6. Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. Elsevier Science, Inc. (37)
  3. American Association for Cancer Research (23)
  4. Nature Publishing Group (21)
  5. Wiley Blackwell (18)
  6. American Society of Clinical Oncology (17)

More Publishers

Results (302)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study
    Journal Article

    Bhatla, T.; Hogan, L. E.; Teachey, D. T.; Bautista, F.; Moppett, J.; Velasco Puyó, P.; Micalizzi, C.; Rossig, C.; Shukla, N.; Gilad, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial
    Journal Article

    Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: The phase 1b BRUIN trial
    Journal Article

    Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M. R.; Lamanna, N.; Tsai, D. E.; Nair, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Acute febrile neutrophilic dermatosis (sweet syndrome) in acute myeloid leukemia patients: A 28-year institutional experience
    Journal Article

    Cowen, E. A.; Barrios, D. M.; Pulitzer, M. P.; Moy, A. P.; Dusza, S. W.; De Wolf, S.; Geyer, M. B.; Markova, A.
    Acta Haematologica (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Journal Article

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    HemaSphere (2024)

    Fulltext@MSK | Save
  • A randomized, multi-center, open label study to compare the safety and efficacy between afatinib monotherapy and combination therapy with HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
    Journal Article

    Kwag, E.; Kim, S. D.; Shin, S. H.; Oak, C.; Park, S. J.; Choi, J. Y.; Hoon Yoon, S.; Kang, I. C.; Jeong, M. K.; Woo Lee, H.; more...
    Integrative Cancer Therapies (2024)

    Fulltext@MSK | Save
  • Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: Final analysis of clinically relevant subgroups in GRIFFIN
    Journal Article

    Chari, A.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D.; Nathwani, N.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Stereotactic body radiation therapy for stage IIA to IIIA inoperable non-small cell lung cancer: A phase 1 dose-escalation trial
    Journal Article

    Rimner, A.; Gelblum, D. Y.; Wu, A. J.; Shepherd, A. F.; Mueller, B.; Zhang, S.; Cuaron, J.; Shaverdian, N.; Flynn, J.; Fiasconaro, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
    Journal Article

    Nooka, A. K.; Kaufman, J. L.; Rodriguez, C.; Jakubowiak, A.; Efebera, Y.; Reeves, B.; Wildes, T. M.; Holstein, S. A.; Anderson, L. D. Jr; Badros, A.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save